3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER_GOV
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
24
Salivary Gland Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Male Urogenital Diseases
2
Bulbo-Spinal Atrophy, X-Linked
2
Adenocarcinoma
2
Urogenital Neoplasms
1
Urogenital Diseases
1
Sleep Initiation and Maintenance Disorders
1
Refractory or Relapsed Solid Tumors
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Neoplasms
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Genital Diseases, Male
1
Fatigue
1
Depression
1
Biochemically Recurrent Prostate Cancer
1
Advanced Solid Tumor
1
Interventions
Oxaliplatin
9
Capecitabine
9
Fluorouracil
7
pembrolizumab
6
Paclitaxel
6
Leucovorin
6
Cisplatin
5
zolbetuximab
4
trastuzumab deruxtecan
3
enzalutamide
3
durvalumab
3
cemiplimab
3
Trastuzumab
3
Gemcitabine
3
Docetaxel
3
fludarabine
2
darolutamide
2
Taxes
2
Ramucirumab
2
Radiotherapy, Image-Guided
2
Radiosurgery
2
Pemetrexed
2
Nivolumab
2
Irinotecan
2
Cyclophosphamide
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vistusertib
1
tucatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
darolutamide
×
90 days
×
Clear all
NCT07617272
2026-06-01
PARIS-BIO
Region Stockholm
Phase 2
Recruiting
100 enrolled
NCT06592924
2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3
Recruiting
830 enrolled